Agios Pharmaceuticals AGIO Institutional Ownership

Updated Oct 11, 2026

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) had 236 institutional holders reporting a position on Form 13F for the quarter ended June 30, 2026.

• Total shares held in AGIO rose 4.62% from Q1 2026; the number of holders rose 11.32% from Q2 2025.
• Of these 236 holders, 132 added to their positions, 67 reduced their stakes and 37 left their positions unchanged.
• In total, institutional investors held 65.95Mn shares of Agios Pharmaceuticals at the end of Q2 2026, up 2.91Mn from the prior quarter and up 5.7Mn from a year earlier.
• As of June 30, 2026, the biggest holder of Agios Pharmaceuticals was BlackRock, Inc. with 6.46Mn shares.
• The biggest increases in AGIO positions during Q2 2026 came from ADAR1 Capital Management, LLC (+1.15Mn shares), UBS Group AG (+853.29K shares), Lynx1 Capital Management LP (+797.37K shares), BlackRock, Inc. (+701.04K shares) and AQR Capital Management LLC (+647.94K shares).
• The largest position reductions in AGIO for Q2 2026 were by Wellington Management Group LLP (-620.61K shares), Erste Asset Management GmbH (-550K shares), Armistice Capital, LLC (-316K shares), Marshall Wace, LLP (-309.32K shares) and BNP Paribas Asset Management Holding S.A. (-300.8K shares).
• Agios Pharmaceuticals' 10 largest institutional shareholders as of Q2 2026 were BlackRock, Inc. (6.46Mn shares), Farallon Capital Management, L.L.C. (5.92Mn shares), State Street Corp (3.53Mn shares), Lynx1 Capital Management LP (3.41Mn shares), D. E. Shaw & Co., Inc. (3.11Mn shares), Vanguard Portfolio Management LLC (2.9Mn shares), Vanguard Capital Management LLC (2.68Mn shares), Armistice Capital, LLC (2.4Mn shares), Erste Asset Management GmbH (2.15Mn shares) and Nomura Asset Management International Inc. (2.11Mn shares), per Business Quant data.